Advertisement

Search Results

Advertisement



Your search for Matthew Stenger matches 193 pages

Showing 51 - 100


colorectal cancer

Nivolumab in Previously Treated Unresectable Metastatic Squamous Cell Carcinoma of the Anal Canal

In a phase II trial reported in The Lancet Oncology, Morris et al found that nivolumab (Opdivo) was active in previously treated unresectable metastatic squamous cell carcinoma of the anal canal. This malignancy is associated with human papillomavirus (HPV) infection, with the rationale for...

colorectal cancer

Optimal Time to Assess Response After Chemoradiotherapy in Anal Squamous Cell Carcinoma

In a post hoc analysis of the UK ACT II trial reported in The Lancet Oncology, Glynne-Jones et al found that the best time to assess for complete response to chemoradiotherapy in patients with anal squamous cell carcinoma is at approximately 26 weeks from the start of treatment. In the ACT II...

colorectal cancer

ASCP/CAP/AMP/ASCO Guideline on Molecular Biomarkers for Evaluation of Colorectal Cancer

As reported in the Journal of Clinical Oncology by Antonia Sepulveda, MD, PhD, of Columbia University, and colleagues, a joint guideline on the use of molecular biomarkers for evaluation of colorectal cancer has been developed by an expert panel from the American Society for Clinical Pathology...

colorectal cancer
lung cancer

Potential Suboptimal Use of Guideline-Endorsed Genomic Testing in Non–Small Cell Lung and Colorectal Cancers

In a study reported in the Journal of Oncology Practice, Gray et al found that many medical oncologists did not use genomic testing endorsed by guidelines in place in 2012 and 2013 in patients with non–small cell lung cancer (NSCLC) and colorectal cancer. The study involved a survey of U.S....

colorectal cancer

Novel Antibody May Reduce Debilitating Symptoms in Patients With Advanced Colorectal Cancer

In a phase III trial reported in The Lancet Oncology, Hickish et al found that treatment with MABp1, an antibody that targets interleukin 1α and exhibits antitumor activity, was associated with improvement in the composite outcome of stabilizing/improving lean body mass and debilitating...

colorectal cancer

Germline Cancer Susceptibility Mutations in Early-Onset Colorectal Cancer

In a study reported in JAMA Oncology, Pearlman et al found that 16% of patients with early-onset colorectal cancer had germline cancer susceptibility mutations, with a wide array of such mutations being identified. The study involved 450 patients diagnosed with colorectal cancer at age < 50...

colorectal cancer

T-Cell Transfer Therapy Targets Mutant KRAS in Metastatic Colorectal Cancer

In a case report in The New England Journal of Medicine, Tran et al at the National Cancer Institute describe response to adoptive transfer of ex vivo expanded tumor-infiltrating lymphocytes containing T cells targeting personalized cancer neoepitopes in a patient with lung metastases from...

colorectal cancer

Effect of Isolated Peritoneal and Nonperitoneal Metastasis and Metastatic Sites on Survival in Patients With Colorectal Cancer

Overall survival was poorer with isolated peritoneal metastasis in colorectal cancer vs other isolated sites of metastasis in patients receiving first-line systemic therapy but similar to that in patients with peritoneal plus another metastatic site and in patients with at least two nonperitoneal...

colorectal cancer

Massachusetts Health Insurance Expansion Associated With Increased Resection and Reduced Emergent Resection for Colorectal Cancer

In a study reported in the Journal of Clinical Oncology, Loehrer et al found that the 2006 Massachusetts health-care reform has resulted in increased rates of resection and reduced emergent resection for colorectal cancer. The study used the Hospital Cost and Utilization Project State Inpatient...

colorectal cancer

Does Adding Adjuvant Bevacizumab to Capecitabine Benefit Patients With Colorectal Cancer?

Kerr et al found that adding adjuvant bevacizumab (Avastin) to capecitabine did not improve disease-free survival in unselected patients with stage III or high-risk stage II colorectal cancer. The results of the phase III QUASAR 2 trial were reported in The Lancet Oncology. Study Details In the...

colorectal cancer

Joint Presence of Metabolic Syndrome and Obesity Seems to Be Associated With Poorer Survival in Early-Stage Colorectal Cancer

In a study in Kaiser Permanante patients reported in the Journal of Clinical Oncology, Cespedes Feliciano et al found that the joint presence of obesity and metabolic syndrome in those with early-stage colorectal cancer was associated with poorer overall and colorectal cancer–specific...

colorectal cancer

NCI Colorectal Cancer Risk Assessment Tool Estimates Current Risk of Advanced Neoplasia

In a study reported in the Journal of the National Cancer Institute, Imperiale et al found that the National Cancer Institute (NCI) colorectal cancer risk assessment tool was able to estimate the current risk for advanced colorectal neoplasia. Study Details The study involved 4,457 persons aged...

colorectal cancer

Better Overall Survival Reported With FOLFIRI Plus Cetuximab vs Plus Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer

In a post hoc analysis of the German phase III FIRE-3 trial reported in The Lancet Oncology, Stintzing et al found that first-line FOLFIRI (fluorouracil, leucovorin, irinotecan) plus cetuximab (Erbitux) was associated with improved overall survival vs FOLFIRI plus bevacizumab (Avastin) in an...

colorectal cancer

Tumor-Infiltrating Lymphocytes and Crohn’s-Like Lymphoid Reaction May Be Prognostic Indicators for Colorectal Cancer

Intratumoral tumor-infiltrating lymphocyte level and prominent peritumoral Crohn’s-like lymphoid reaction appear to be independent prognostic factors for survival in colorectal cancer, according to a study reported by Rozek et al in the Journal of the National Cancer Institute. The findings...

colorectal cancer

No Improvement in Outcome Reported With Longer Wait Between Radiochemotherapy and Surgery in Rectal Cancer

Pathologic complete response rate was not improved by increasing the interval between neoadjuvant chemoradiotherapy and surgery from 7 to 11 weeks in patients with rectal cancer, according to the French phase III GRECCAR-6 trial reported by Lefevre et al in the Journal of Clinical Oncology. In...

colorectal cancer

Gene-Expression Signature Assay Identifies High-Risk Stage II Colon Cancer

In an analysis reported in the Journal of Clinical Oncology, Niedzwiecki et al found that the ColDx gene-expression signature assay identified high-risk stage II colon cancer among patients in the phase III Alliance C9581 trial. This assay has been shown to be independently prognostic for...

colorectal cancer

USPSTF Issues New Recommendations for Colorectal Cancer Screening

As reported in JAMA, the U.S. Preventive Services Task Force (USPSTF) has issued new recommendations for colorectal cancer screening. In brief, the USPSTF recommends colorectal cancer screening starting at age 50 years and continuing until age 75 years (grade A recommendation = “The USPSTF...

colorectal cancer
solid tumors

Norwegian Study Shows Benefit of Aspirin as Secondary Prevention in Patients With Colorectal Cancer

A Norwegian population-based study reported in the Journal of Clinical Oncology by Bains et al showed that use of aspirin after diagnosis of colorectal cancer was associated with improved colorectal cancer–specific survival. Study Details In the population-based retrospective cohort study,...

colorectal cancer

Study Finds Adding Adjuvant Oxaliplatin to Fluoropyrimidine of Benefit in Deficient Mismatch Repair Colon Cancer

In a French retrospective study reported in the Journal of the National Cancer Institute, Tougeron et al found that the addition of adjuvant oxaliplatin to fluoropyrimidine treatment improved disease-free survival in patients with stage III deficient mismatch repair colon cancer. Study Details...

colorectal cancer

Study of SEER Data Identifies Racial/Ethnic Disparities in Survival in Patients With Young-Onset Colorectal Cancer

In a study of Surveillance, Epidemiology, and End Results (SEER) data reported in the Journal of Clinical Oncology, Holowatyj et al found that survival was significantly poorer in black vs white patients diagnosed with colorectal cancer between the ages of 20 and 49 years. Study Details The...

colorectal cancer

Little Apparent Activity of Cetuximab in Refractory Metastatic Colorectal Cancer With KRAS G13D Mutation

Cetuximab (Erbitux) exhibited little apparent activity in refractory metastatic colorectal cancer harboring the KRAS G13D mutation, according to the findings of the phase II Australasian Gastro-Intestinal Trials Group ICECREAM study, which were reported by Segelov et al in the Journal of Clinical...

colorectal cancer

Trastuzumab/Lapatinib Active in Refractory, KRAS Codon 12/13 Wild-Type, HER2-Positive Metastatic Colorectal Cancer

Dual HER2 inhibition with trastuzumab (Herceptin) and lapatinib (Tykerb) was active in patients with refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer, according to an Italian phase II trial reported by Sartore-Bianchi et al in The Lancet Oncology. Study Details...

colorectal cancer

Increased Rate of Nonoperative Management of Rectal Adenocarcinoma

A National Cancer Database analysis reported by Ellis et al in the Journal of Clinical Oncology indicates a doubling in the use of chemoradiation only in patients with nonmetastatic rectal cancer over recent years. However, current evidence is insufficient to support such nonoperative management....

colorectal cancer

Next-Generation Sequencing Assay May Permit Accurate Detection of Mismatch Repair Deficiency in Colorectal Cancer

Use of a custom next-generation sequencing assay may accurately predict mismatch repair deficiency on the basis of mutational load in colorectal cancer, according to a report by Stadler et al in the Journal of Clinical Oncology. Study Details The study involved data from 224 patients with...

colorectal cancer

Japanese Trial Shows Reduced Risk of Subsequent Colorectal Adenomas and Polyps With Low-Dose Metformin

Treatment with low-dose metformin reduced the risk of metachronous colorectal adenomas and polyps over 12 months in nondiabetic patients who had undergone endoscopic polypectomy, according to a report by Higurashi et al in The Lancet Oncology. Study Details In the double-blind phase III trial,...

colorectal cancer
solid tumors

Poorer Outcome With BRAF and KRAS Mutations in Microsatellite-Stable but Not Microsatellite-Unstable Colon Cancer

In an analysis of the PETACC-8 trial reported by Taieb et al in JAMA Oncology, BRAF V600 and KRAS mutations were associated with shorter disease-free and overall survival in patients with microsatellite-stable colon cancer—but not in those with tumors with microsatellite instability—in...

colorectal cancer
gastrointestinal cancer

Long-Term Follow-up of Prospective U.S. Cohorts Shows Reduced Risk of GI Tract Cancers With Regular Aspirin Use

In a long-term follow up of two large U.S. prospective cohorts reported in JAMA Oncology, Cao et al found that regular use of aspirin was associated with a reduced risk of gastrointestinal (GI) tract cancers. In 2015, the U.S. Preventive Services Task Force recommended the use of aspirin in...

colorectal cancer

High Expression of Epiregulin or Amphiregulin Predicts Benefit of Panitumumab in RAS Wild-Type Advanced Colorectal Cancer

In the UK phase III PICCOLO trial reported in JAMA Oncology, Seligmann et al found that high expression of either of the epidermal growth factor receptor (EGFR) ligands epiregulin or amphiregulin was associated with a progression-free survival benefit with panitumumab (Vectibix)/irinotecan vs...

colorectal cancer

Selective Internal Radiotherapy Does Not Improve Any-Site but Prolongs Liver-Specific Progression-Free Survival in Metastatic Colorectal Cancer

In the phase III SIRFLOX trial reported in the Journal of Clinical Oncology, van Hazel et al found that adding selective internal radiation therapy with yttrium-90 resin microspheres to FOLFOX (fluorouracil, leucovorin, oxaliplatin) with or without bevacizumab (Avastin) did not improve any-site...

colorectal cancer

Factors Associated With Early Mortality in Patients Receiving Adjuvant Therapy for Colon Cancer

In an analysis of the ACCENT (Adjuvant Colon Cancer Endpoints) database reported in the Journal of Clinical Oncology, Cheung et al found that factors associated with early mortality in patients in trials of adjuvant systemic therapy included age, performance status, tumor grade, stage, and ratio of ...

colorectal cancer

Transcription Factor CDX2 May Be Prognostic Biomarker in Stage II and III Colon Cancer

In a study reported in The New England Journal of Medicine, Dalerba et al found that absence of the transcription factor CDX2, although prognostic for poor outcome in stage II and III colon cancer vs cancers with CDX2 expression, identified a subgroup of high-risk patients who appeared to benefit...

colorectal cancer

Treatment Trends in Stage II and III Colorectal Cancer in the United States

As reported by Murphy et al in the Journal of the National Cancer Institute, an analysis of Surveillance, Epidemiology, and End Results (SEER) data from patients with stage II or III colorectal cancer indicated that the use of adjuvant chemotherapy in colon cancer declined slightly between 2005 and ...

colorectal cancer
issues in oncology

Women’s Health Initiative Clinical Trial Suggests Endogenous Estrogens May Protect Against Colorectal Tumorigenesis in Postmenopausal Women

In a nested case-control study in the Women’s Health Initiative Clinical Trial, reported in Journal of the National Cancer Institute by Murphy et al, endogenous estrogen levels were inversely associated with and sex hormone–binding globulin (SHBG) levels were positively associated with...

colorectal cancer

Benefit of Maintenance Bevacizumab-Erlotinib vs Bevacizumab After Bevacizumab-Based Induction Therapy in Metastatic Colorectal Cancer

As reported by Tournigand et al in The Lancet Oncology, final analysis of the phase III GERCOR DREAM (OPTIMOX3) trial suggested a benefit of maintenance bevacizumab (Avastin)-erlotinib vs bevacizumab after bevacizumab-based induction therapy in patients with previously untreated metastatic...

colorectal cancer
issues in oncology

10-Year Results of MOSAIC Trial Show Continued Survival Benefit of Adjuvant FOLFOX4 in Stage III Colon Cancer

Ten-year results of the MOSAIC trial, reported in the Journal of Clinical Oncology by André et al show a continued overall survival benefit with adjuvant FOLFOX4 (fluorouracil [5-FU] leucovorin plus oxaliplatin) vs 5-FU/leucovorin in patients with stage III colon cancer and in the entire...

colorectal cancer

Pooled Analysis Indicates That Low but Not High BMI Is Associated With Poorer Outcome in Metastatic Colorectal Cancer

In a study reported in the Journal of Clinical Oncology, Renfro et al found that low but not high body mass index (BMI) was associated with poorer progression-free and overall survival in patients receiving first-line treatment for metastatic colorectal cancer. The analysis included individual...

colorectal cancer

Phase III Trials Fail to Show Noninferiority of Surgical Outcome for Laparoscopic vs Open Resection in Rectal Cancer

Two phase III trials, reported in JAMA by Fleshman et al and Stevenson et al, failed to show noninferiority of surgical outcome for laparoscopic vs open resection in patients with rectal cancer. ACOSOG Z6051 Trial In the American College of Surgeons Oncology Group (ACOSOG) Z6051 trial, reported...

colorectal cancer

No Reduction in Recurrent Colorectal Adenomas With Vitamin D and Calcium Supplementation

In a trial reported in The New England Journal of Medicine, Baron et al found that daily vitamin D and calcium supplementation did not reduce recurrence of colorectal adenomas in patients with recently diagnosed adenomas and no known polyps remaining after complete colonoscopy. Study Details In...

colorectal cancer

Good Outcome With Neoadjuvant Chemoradiation and Local Excision in Clinical T2,N0 Distal Rectal Cancer

In a multi-institutional phase II trial (ACOSOG Z6041) reported in The Lancet Oncology, Garcia-Aguilar et al found that neoadjuvant chemoradiotherapy and local excision was associated with an acceptable disease-free survival rate, albeit not so high as anticipated, in patients with clinical stage...

colorectal cancer

Study Compares Maintenance Strategies After First-Line Oxaliplatin/Fluoropyrimidine/Bevacizumab in Patients With Metastatic Colorectal Cancer

In a German noninferiority phase III trial (AIO 0207) reported in The Lancet Oncology, Hegewisch-Becker et al found that maintenance treatment with bevacizumab (Avastin) was noninferior to a fluoropyrimidine plus bevacizumab in time to maintenance strategy failure following first-line treatment...

colorectal cancer
issues in oncology

Extended RAS Mutation Testing in Metastatic Colorectal Cancer to Predict Response to Anti-EGFR Antibody Therapy

As reported in the Journal of Clinical Oncology by Allegra et al, ASCO has issued a provisional clinical opinion (PCO) update on extended RAS mutation testing in metastatic colorectal cancer to predict response to anti-EGFR monoclonal antibody treatment. The update revises a 2009 PCO and is based...

colorectal cancer

Activity of Combined BRAF and MEK Inhibition in BRAF V600–Mutant Metastatic Colorectal Cancer

In a phase I/II study reported in the Journal of Clinical Oncology, Corcoran et al found that the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) produced responses in some patients with BRAF V600–mutant metastatic colorectal cancer. MAPK...

colorectal cancer
issues in oncology

Study Finds Racial Differences in BRAF/KRAS Mutation and Disease-Free Survival in Patients With Stage III Colon Cancer

In a study reported in the Journal of the National Cancer Institute, Yoon et al found that among patients with stage III colon cancer in the Alliance N0147 trial, Asians had the lowest rate of BRAF/KRAS mutations and longer disease-free survival vs whites among patients with N2 disease and that...

colorectal cancer

Final Results of NO16968 Trial Show Improved Overall Survival With Adjuvant XELOX vs Bolus 5-FU/Leucovorin in Stage III Colon Cancer

As reported by Schmoll et al in the Journal of Clinical Oncology, the final results of the phase III NO16968 trial showed that adjuvant therapy with XELOX (capecitabine, oxaliplatin) improved overall survival vs fluorouracil (5-FU)/leucovorin in patients with resected stage III colon cancer....

colorectal cancer

Improved Overall Survival With FOLFOXIRI/Bevacizumab vs FOLFIRI/Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

In an updated analysis of the Italian phase III TRIBE trial reported in The Lancet Oncology, Cremolini et al found that FOLFOXIRI (fluorouracil [5-FU], leucovorin, oxaliplatin, irinotecan) plus bevacizumab (Avastin) significantly prolonged overall survival in patients with unresectable metastatic...

colorectal cancer

Aspirin Reduces Obesity-Related Colorectal Cancer Risk in Patients With Lynch Syndrome

In an analysis of a randomized trial of aspirin in patients with Lynch syndrome reported in the Journal of Clinical Oncology, Movahedi et al found that obesity was associated with an increased risk of colorectal cancer, with the excess risk being restricted to those not receiving aspirin. ...

colorectal cancer

Adding Oxaliplatin to Preoperative Chemoradiotherapy and Postoperative Chemotherapy Improves Disease-Free Survival in Locally Advanced Rectal Cancer

Final results of the German phase III CAO/ARO/AIO-04 trial reported in The Lancet Oncology by Rödel et al showed that adding oxaliplatin to fluorouracil (5-FU)–based neoadjuvant chemoradiation and postoperative chemotherapy improved disease-free survival in patients with locally advanced ...

colorectal cancer
issues in oncology

Reemergence of Racial Disparity in Use of Adjuvant Chemotherapy in Stage III Colon Cancer

In an analysis reported in the Journal of Clinical Oncology, Murphy et al found that disparity in the use of adjuvant chemotherapy in white vs black patients with stage III colon cancer may have recently reemerged after a trend of increasing use in both racial groups.   Changes in Use Over...

colorectal cancer

Adding Neoadjuvant mFOLFOX6 After Chemoradiation May Improve Pathologic Complete Response Rate in Locally Advanced Rectal Cancer

In a phase II trial reported in The Lancet Oncology, Garcia-Aguilar et al found that adding neoadjuvant mFOLFOX6 (modified fluorouracil [5-FU], leucovorin, oxaliplatin) after chemoradiation improved the pathologic complete response rate in patients with locally advanced rectal cancer undergoing...

issues in oncology
colorectal cancer

Circulating DNA and Protein Biomarkers May Be Associated With Benefit of Regorafenib in Metastatic Colorectal Cancer

In a retrospective study reported in The Lancet Oncology, Tabernero et al used commercially available BEAMing technology to assess plasma tumor DNA and protein levels in a subgroup of patients from the CORRECT trial of regorafenib (Stivarga) in metastatic colorectal cancer and examined the...

Advertisement

Advertisement



;
Advertisement